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Nuclear receptors (NRs) are a large family ligand-activated
transcription factors that regulate several important processes,
including development, reproduction and metabolism [1–3]. NRs
respond to lipophilic hormones, vitamins, dietary lipids, or other
intracellular signals [4]. By virtue of this ligand-dependent activity,
NRs serve as a molecular bridge between the whole body environ-
ment and the genome [5,6]. Genetic studies in humans and mice
demonstrated that NRs control a wide variety of metabolic processes
by regulating the expression of genes encoding enzymes, transporters
and other proteins involved inmetabolic homeostasis [7,8]. Indeed, an
important role of this family of proteins in metabolic disease is
exempliﬁed by NR ligands used in the clinic or under exploratorydevelopment for the treatment of diabetes mellitus, dyslipidemia or
hypercholesterolemia [9]. In addition to their roles in metabolic
processes, some NRs also regulate several innate and adaptive
immune responses [10]. Thus, there is increasing interest in deﬁning
the speciﬁc transcriptional programs controlled by NRs in immune
cells.
Nearly all members of the NR family present a conserved
architecture divided in functional domains: an N-terminal region
that frequently contains a ligand-independent activation function
(AF-1), a DNA binding domain (DBD), a C-terminal ligand binding
domain (LBD) that accommodates small lipophilic molecules and a
ligand-dependent transcriptional activation function, AF-2 (1). NR
members can be divided in three main subfamilies: The broadly
characterized subfamily of steroid hormone receptors that mediate
most of the biological actions of steroid hormones, shuttle between
the cytoplasm and nucleus and bind DNA as homodimers, such as the
ﬁrst identiﬁed member the glucocorticoid receptor (GR)[11,12]. A
second subfamily of structurally related receptors whose endogenous
ligands are still not identiﬁed (or may not be even required for their
activity) and are considered “orphan” receptors. A third set of NRs
considered as “adopted” orphan receptors, that were identiﬁed prior
to the discovery of their regulatory ligands and now have been
deorphanized with the aid of chemical, structural and genomic
technologies [13,14]. In many cases, the ligands have turned out to be
intermediates or end products of metabolic pathways [15]. This subset
of adopted NRs is constitutively nuclear and binds to DNA as obligate
heterodimers with the retinoid X receptor (RXR). RXR heterodimers
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AGGTCA in the regulatory regions of their target genes [14]. The
spacing and orientation of the response elements dictates which
heterodimer will bind to the site [14]. In the absence of ligand, they
are believed to be bound to DNA and complexed with corepressor
proteins, such as silencing mediator of retinoic acid and thyroid
hormone receptor (SMRT) and nuclear receptor corepressor (NCoR)
[16,17]. Under these conditions, transcription of target genes is
actively repressed. Ligand binding induces a structural change that
displaces the corepressor, facilitates interaction with coactivators
including the steroid receptor co-activator (SRC) family of proteins
and promotes the transcription of target genes [18]. Among this set of
receptors, the Peroxisome Proliferators Activated Receptors (PPARs)
and liver X receptors (LXRs) have been extensively studied during the
last decade [19–22]. Here we review the general features of LXR
biology (alongwith parallel or prior workmainly from PPARs and GR),
and also the work that has enhanced our understanding of LXR
functions in macrophages with special attention to the crosstalk
between inﬂammatory and metabolic pathways and recent develop-
ments that point to LXRs as important regulators of innate and
adaptive immune responses.
2. General aspects of LXRs as transcription factors
The LXR nuclear receptors, LXRα (NR1H3) and LXRβ (NR1H2), are
encoded in separate chromosomes and were both identiﬁed around
15 years ago. The LXRα isoform was discovered by two independent
groups and named it RLD-1[23] and LXR [24] whereas other groups
identiﬁed the LXRβ isoform and called it UR [25], NER [26], OR-1 [27],
and RIP-15 [28]. LXRs bind to DNA as obligate heterodimers with RXRs
and the LXR/RXR heterodimer activity can be regulated by ligands for
either receptor [29]. In nearly all LXR target genes identiﬁed until now
LXRα/RXR and LXRβ/RXR can interact with similar afﬁnities to the
response elements (LXRE) in their promoter regions containing the
HREmotif AGGTCA separated by four nucleotides (DR-4) [24]. Various
modiﬁed forms of cholesterol, including 22-(R), 24-(S) and 27-
hydroxycholesterol and 24-(S), 25-epoxycholesterol can induce LXR
transcriptional activity endogenously at physiological concentrations
[30–32]. Recently, elevated concentrations of D-glucose and β-
sitosterol were also reported to be activators of LXRs [33,34]. In
addition, potent synthetic LXR ligands have been developed, including
T0901317 and GW3965 [35,36]. These ligands that do not present LXR
isoform selectivity have been widely used over the last decade to
clarify the biological actions of LXRs.
LXRα and LXRβ share more than 75% sequence similarities in their
DBD and LBD both in humans and rodents [37]. Despite these
similarities, LXR tissue distribution differs signiﬁcantly. While LXRβ is
more ubiquitously expressed, LXRα expression predominates in
metabolic tissues such as the liver, adipose tissue, intestine, kidney,
and tissue macrophages [7]. However, the mechanisms that control
the expression of both LXR isoforms are not completely understood.
Whereas LXRβ seems to be constitutive in many cell types, expression
of LXRα in macrophages is induced by synthetic PPARγ ligands [38]
and also during some inﬂammatory situations, such as bacterial
infections [39]. In human, but not in mouse cells, the expression of
LXRα gene is auto regulated, suggesting that the biological actions of
LXR activators may have more implications in these cells [40,41]. In
addition, studies have shown that LXRα is phosphorylated on serine
198 in the hinge region [42,43], although the in vivo relevance of LXR
phosphorylation is still unclear. Also, a recent study has demonstrated
that LXRs are targets for O-linked beta-N-acetylglucosamine modiﬁ-
cation, a process that can have further implications in glucose-sensing
mechanisms [44]. Together, these studies show that the expression
of LXRα is not only species and tissue speciﬁc, but it is also likely to
be regulated at several levels in response to certain metabolic and
inﬂammatory signaling pathways.3. LXRs as transcriptional regulators of cholesterol homeostasis
Over the past 10 years, considerable evidence indicates that LXRα
and LXRβ are crucial regulators of cholesterol metabolism in
mammals. The identiﬁcation of the CYP7A1 gene (a member of the
cytochrome P450 family that is crucial for bile acid synthesis) as a
direct target for LXR in mice provided the ﬁrst insight into the role of
LXRs in cholesterol metabolism [45]. However, direct regulation of
CYP7A1 expression by LXRs is not conserved in human cells.
Subsequent studies in LXR-deﬁcient mice and in cells treated with
synthetic LXR ligands have revealed that LXRs play an important role
in the pathway of reverse cholesterol transport, in which excess
cholesterol is transported in high-density lipoprotein (HDL) particles
from peripheral cells to the liver for excretion in bile [37,46]. The LXR
effects on reverse cholesterol transport are likely dependent on the
ability of LXRs to control the expression of various enzymes in
different tissues. For example LXRs control the expression of ABCG5
and ABCG8 membrane transporters, which, in addition to the above
mentioned CYP7A1, promote cholesterol elimination through the bile
[47]. In the intestine, LXR-dependent induction of ABCG5 and ABCG8
results in decreased absorption of cholesterol by intestinal cells.
Importantly, LXRs also regulate the expression of several genes
involved in reverse cholesterol transport in peripheral cells such as
macrophages [48]. In response to an elevation in intracellular
cholesterol content, LXRs induce expression of the cholesterol efﬂux
transporters ABCA1 [49–52] and ABCG1 [53], the apolipoproteins
apoE and apoCs [54,55], and the lipoprotein remodeling enzyme PLTP
[32,35].
Although the above mentioned studies focused on cholesterol
metabolism, LXRs have also a signiﬁcant role in the control of fatty
acid metabolism. Mice carrying a targeted disruption in the LXRα
gene are deﬁcient in expression of SREBP-1c (sterol regulatory
element binding protein) [56], FAS (fatty acid synthase) [57], SCD-1
(stearoyl CoA desaturase-1) [7], and ACC (acetyl CoA carboxylase)
[45]. Administration of the synthetic LXR ligands to mice elevates
plasma triglyceride levels in part through the induction of the hepatic
lipogenic pathway. The master regulator of this lipogenic pathway
SREBP-1c, as well as FAS and PLTP have been shown to be direct
targets of LXR [35,56–58]. The LXR-dependent increase in hepatic
triglycerides constitutes an obstacle for the development of LXR
ligands as therapeutic agents. However, since LXRα is the dominant
isoform expressed in the liver, where LXRβ is expressed poorly [7], it
is thought that an LXRβ-selective agonist may retain efﬁcacy without
increasing hepatic lipogenesis [59]. Therefore, it is possible that the
identiﬁcation of LXRβ-selective agonists can have signiﬁcant thera-
peutic value.
4. LXRs and macrophage gene expression
Macrophages are professional phagocytic cells that are present in
virtually all tissues and that play crucial roles host defense [60]. They
differentiate from circulating peripheral blood mononuclear cells,
which migrate into tissues in the steady state or in response to
inﬂammation [61,62]. In addition to their role as effector immune
cells, macrophages also play important metabolic roles due to their
exceptional phagocytic capacity and dynamic lipid metabolism
[63,64]. Thus, it is important to highlight that macrophages, not
only orchestrate inﬂammatory responses and host defense against
pathogens but are also critical for the clearance of apoptotic cells and
oxidized lipoproteins. These characteristics make the macrophage a
prototypic effector cell that link innate immune responses with
metabolism and tissue homeostasis. In this regard, the role of LXR in
macrophage biology has special relevance in the context of athero-
sclerosis, now recognized to be a chronic inﬂammatory disease as well
as a disorder of lipid metabolism [65]. The accumulation of large
amounts of cholesterol under hypercholesterolemic conditions is a
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the early stages of atherogenesis [66]. To deal with this cumulative
progression, LXRs reduce the cellular cholesterol levels by promoting
cholesterol efﬂux via the upregulation of the ABC family transporters,
resulting in increased reverse cholesterol transport. Ten years ago,
independent studies demonstrated that ABCA1 is a direct target for
regulation by LXRα and LXRβ [49–52]. ABCA1 expression and
cholesterol efﬂux are induced in macrophages in response to oxLDL,
oxysterols and synthetic LXR ligands and this regulation is lost in LXR-
deﬁcient macrophages. Importantly, the ability of LXRs to promote
cholesterol efﬂux is not observed in cells obtained from Tangier
disease patients (that lack functional ABCA1), demonstrating that
ABCA1 is essential for LXR-mediated efﬂux [49]. The relevance of
ABCA1 in atherosclerosis is highlighted by several studies in murine
models, including a myeloid-speciﬁc ABCA1 deﬁciency that results in
increased atherogenesis, while transgenic expression of the ABCA1
gene reduced lesion formation [67–69].
Lipid loading and LXR ligands also induced the expression of
ABCG1 transporter in macrophages [53]. Regulation of ABCG1
expression could result in additional pathway for cholesterol efﬂux
frommacrophages ormay act in concert with ABCA1. Characterization
of ABCG1−/− mice revealed massive lipid accumulation in their
lungs without affecting plasma lipid/lipoprotein levels [70]. Three
independent studies revealed discordant results regarding the role of
ABCG1 in murine models of atherosclerosis [71–73]. However, work
with double mutant Abcg1−/−Abca1−/− mice demonstrated that
loss of both sterol transporters resulted in increased lipid accumula-
tion in macrophages than in ABCA1 and ABCG1 single knockout cells
[74,75], demonstrating that both transporters are important for sterol
homeostasis.
Additionally, macrophage LXRs contribute to the reverse choles-
terol transport pathway by a mechanism that involves the induction
of a subset of apolipoproteins capable of serving as acceptors for
cholesterol and lipoprotein remodeling enzymes. LXR agonists induce
the expression of ApoE in macrophages and adipose tissue but not in
liver [54] and several studies have demonstrated the important role of
apoE in macrophage cholesterol efﬂux. For example, mice over-
expressing apoE speciﬁcally in macrophages show signiﬁcantly
reduced lesion formation, while deletion of apoE in the macrophage
resulted in increased susceptibility to the disease [76]. Other studies
have demonstrated that LXRs regulate the expression of ApoC cluster
(ApocI, ApocII, and ApocIV) in macrophages [55] and it is likely that
they participate to some extent in LXR-dependent reverse cholesterol
transport. Other targets for LXR regulation in the macrophage are the
lipoprotein lipase (LPL) and phospholipid transfer protein (PLTP)
[58,77]. It is possible that expression of these enzymes in macro-
phages within the artery wall help to clear serum cholesterol-rich
lipoproteins by facilitating the reverse cholesterol pathway [78,79].
Together, these studies suggest that LXRs regulate macrophage
cholesterol efﬂux not only by inducing cholesterol transporter
proteins (ABCA1 and ABCG1) but also through increased production
of cholesterol acceptors (apoE and apoCs) and lipoprotein remodeling
proteins (PLTP and LPL) [19].
In addition to the relevance of LXR function in cellular cholesterol
efﬂux and ABC transporter expression, recent work has uncovered a
novel mechanism by which LXR also modulates cellular cholesterol
uptake in several cell types. In a series of elegant studies, Zelcer et al.
demonstrated that LXR decreases cholesterol uptake by inducing the
expression of a novel E3 ubiquitin ligase that they designated as “Idol”
(inducible degrader of the LDL receptor). Expression of Idol in several
cell types, including macrophages, induces the ubiquitination of the
LDLR, resulting in its degradation by the proteosome pathway and
subsequent reduction in LDL cholesterol binding and uptake [80].
Overexpression of Idol in vivo in mice decreases LDLR protein levels
and signiﬁcantly increases plasma cholesterol. Subsequent studies by
the same authors demonstrated that Idol also targets two othermembers of the LDLR family, very low density lipoprotein receptor
VLDL and apoER2, for degradation in a similar manner to that of LDLR
[81]. This new mechanism that can control cholesterol levels through
the LXR–Idol pathway may represent a novel therapeutic drug target
in cardiovascular disease.
5. LXRs and atherosclerosis
The studies outlined above showed that LXR activity regulates the
expression of genes involved in reverse cholesterol transport, bile acid
metabolism, and intestinal cholesterol absorption. All these processes
are considered anti-atherogenic. However, LXRs also promote fatty
acid and triglyceride synthesis, which are considered independent
risk factors for cardiovascular disease. During the last decade, these
two apparent contrasting effects have stimulated independent efforts
to elucidate the role of LXR activity in the context of hypercholester-
olemia. However, the observation that LXRαβ−/− mice, even fed a
regular diet, accumulate lipid loaded macrophages in several tissues
over time [82,83] indicates that LXR-dependent pathways are crucial
for normal cholesterol homeostasis. It is now clear from more than a
dozen studies that the expression and activation of LXR is crucial to
prevent atherogenesis (see a speciﬁc review by Calkin and Tontonoz)
[84]. The initial demonstration that LXR activity inhibited the
development of atherosclerosis in mice came from work by Joseph
et al. [85] who showed that LXR agonist GW3965 was able to decrease
lesion formation in both apoE−/− and LDLR−/−mice. Furthermore,
GW3965 treatment increased expression of ABCA1 and ABCG1 in the
aortas of these atherosclerotic mice, suggesting that direct actions of
LXR ligands on vascular gene expression are likely to contribute to
their anti-atherogenic effects. Subsequent studies also observed a
reduction in lesion formation in murine models of atherosclerosis
using other synthetic ligands, such as T0901317, DMHCA, WAY-
252623 or ATI-829 ([86] and reviewed in ref. [84]). Interestingly,
some of these studies demonstrated that LXR agonist treatment is able
to modulate preexisting atherosclerotic lesions, resulting in remodel-
ing and regression of these plaques. Other studies have investigated
the inﬂuence of gain or loss of LXR function on atherosclerosis models
by using transgenic/adenoviral or knockout strategies [82,83,87–89].
Two different studies demonstrated that global LXRα deﬁciency on
either apoE−/− and LDLR−/− was associated with accelerated
atherosclerosis, suggesting that LXRβ is not sufﬁcient to compensate
for the loss of LXRαunder thosehypercholesterolemic settings [89,90].
In one of them, Bradley et al. [90] also showed in the ApoE−/−model
that LXRα deﬁciency was associated with massive cholesterol
accumulation in peripheral tissues. Both studies showed decreased
lesion formation without triglyceride accumulation by stimulating
LXRβ activity with synthetic agonists in an LXRα-deﬁcient
background.
The physiological relevance of endogenous hematopoietic LXRs
during atherogenesis was shown by Tangirala et al. [82]. Transplan-
tation of bone marrow from LXRα,β−/− mice into apoE−/− and
LDLR−/− mice resulted in a signiﬁcant increase in lesion develop-
ment [82]. Interestingly, the same authors found that isolation of LXR-
deﬁcient macrophages under those hypercholesterolemic conditions
presented increased cholesterol accumulation. Another study by
Teupser et al. [88] investigated the contribution of macrophage
LXRα on the development of atherosclerosis. In this report, the
authors found that overexpression of LXRα gene under the control of
a macrophage-speciﬁc promoter in LDLR−/− mice resulted in a
striking reduction in atherosclerosis lesion formation [88]. Another
recent study by Moschetta and colleagues demonstrated that
intestinal-speciﬁc LXR activation alleviates atherosclerosis by induc-
ing the reverse cholesterol transport pathway without inducing
hepatic steatosis [91]. These observations, together, indicate that the
LXR pathway may be a tractable target for intervention in cardiovas-
cular disease.
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endoplasmic reticulum (ER) stress in response to toxic lipids or
inﬂammatory stimuli constitutes an additional mechanism involved
in the atherogenic process (see recent review by Ira Tabas and
references therein [92]). Regarding LXR and ER stress, a recent study
by Erbay et al. [93] showed that inhibition of the fatty acid binding
protein FABP4 (also called aP2) in macrophages decreases the ER
stress and reduces atherosclerotic lesion formation in murine models.
The authors proposed a mechanism by which FABP4 inhibition
alleviates atherosclerosis through the induction of SCD-1 expression
by LXRα inmacrophages. Upregulation of LXRα/SCD-1 pathway in the
context of FABP4 inhibition leads to increased conversion of saturated
fats into monounsaturated lipids. Previous studies from the same
group reported elevated PPARγ activity, increased expression of
LXRα, enhanced cholesterol efﬂux and reduced inﬂammation in
FABP4−/− macrophages [94,95]. The mechanism by which FABP4
represses LXRα expression and the contribution of other atheropro-
tective actions of LXR and/or PPAR signaling pathways in the context
of FABP4 inhibition, however, is still unclear.
Together, these studies indicate that macrophage LXRs play an
important role as anti-atherogenic factors through several mecha-
nisms, including the induction of reverse cholesterol transport and by
reducing the inﬂammatory environment (see below).
6. Macrophage activation pathways “at a glance”
As outlined above, macrophages are professional phagocytic cells
that play crucial roles in host defense and also participate in the
regulation of the inﬂammatory response and the maintenance of
tissue homeostasis [60]. As sentinels of the immune system in
multiple locations, macrophages present striking heterogeneity in
their functions. Some of them are considered pro-inﬂammatory, such
as the release of reactive toxic species or cytokine and chemokine
production. These functions are crucial for efﬁcient elimination of
pathogens and communication with other components of the
immune system. In contrast, macrophages also participate in the
resolution of inﬂammation, wound healing and the maintenance of
peripheral self tolerance through several different mechanisms. Thus,
macrophages can display different specialized forms of activation (so
called ‘macrophage polarization’) and plasticity in response to host
homeostatic signals or external environmental challenges [61].
It is now clearly established that chronic inﬂammatory reactions
triggered by tissue resident macrophages constitute a critical step in
the development and perpetuation of many diseases. For example,
atherosclerosis, type-2 diabetes and autoimmune disorders are
chronic inﬂammatory diseases in which macrophages and other
immune cells present aberrant regulation of metabolic and inﬂam-
matory pathways [22]. The incidence of these chronic disorders has
increased dramatically in industrialized countries and a high
percentage of these people present susceptibility to several combined
chronic disorders such as metabolic syndrome and cancer. Therefore,
there is substantial interest in understanding the molecular mecha-
nisms that link metabolic processes with macrophage inﬂammatory
responses. Indeed, alleviation of inﬂammation or inhibition of
macrophage activation pathways leads to signiﬁcant beneﬁcial
responses in obesity, insulin resistance and atherosclerosis [22,96].
The ability of macrophages to adopt different activation programs
requires ways to classify them into distinct subtypes. One of these
functional subsets is the classically activated macrophages (M1) that
develop in response to interferon gamma (IFNγ) released by Th1 cells
or microbial components (such as bacterial lipopolysaccharide, LPS)
and produce several inﬂammatory cytokines, microbicidal species and
favor antigen presentation and cellular immunity. M1 responses are
therefore essential to combat intracellular infections such as Myco-
bacterium tuberculosis and HIV [61]. M1 macrophage responses,
however, can also be injurious to normal cells and tissues if uncheckedat the resolution of immune responses and contribute to the
pathogenesis of several metabolic diseases, including atherosclerosis
and obesity-induced insulin resistance [22].
A second subset of macrophage responses is displayed by the
alternatively activated (M2) macrophages, whose maturation is
controlled by IL-4 and IL-13 cytokines, and interfere with IFNγ-Th1
mediated responses [61]. In addition, M2 activated macrophages
present increased expression of MHC-II, some sugar binding proteins
(such as DC-SIGN, Mannose Receptor and Dectin-1), and enzymes and
molecules involved in anti-inﬂammatory and anti-parasitic mecha-
nisms (Arginase-1, Fizz1 and Ym1/2) [97]. Thus, the M2 macrophage
phenotype is usually linked to Th-2 responses and is particularly
relevant in cellular and humoral responses to parasitic and extracel-
lular infections. Although the M1/M2 macrophage categories can be
generally associated to their functional phenotypes observed during
intracellular or extracellularmicrobial infections, there are distinct (or
perhaps a mixture of both phenotypes) macrophage responses
important in non-infectious pathologies. Some examples of “mixed”
macrophage phenotypes are observed in chronic pathologies, such as
foam cells in atherosclerosis, tumor-associated macrophages in
cancer, adipose tissue macrophages during obesity/T2D or activated
microglia in models of Parkinson's/Alzheimer's diseases (readers are
referred to recent reports for amore specialized revision [22,98–100]).
Due to their remarkable heterogeneity, it is also evident that
different resident tissue macrophages throughout the body should
have distinct phenotypes under homeostatic conditions. For example,
alveolar macrophages in the lung (the main sentinels in the airways)
are continuously exposed to some airborne particles and perhaps
present some constitutive activation but also have important lipid
functions in collaboration with pneumocytes [101]. In contrast,
microglia cells in the CNS are probably exposed to an anti-
inﬂammatory environment as they are the main immune cells in
the vulnerable nervous tissue and also due to their special location, as
they are separated from the rest of the body through the blood–brain
barrier [99]. Therefore, tissue macrophages can present features of
M1/M2 polarization, but also some of them may need to adopt an
inactivated or “deactivated” state under certain situations to prevent
some unwanted actions of the specialized M1/M2 activation [61]. This
macrophage deactivated phenotype, characterized by decreased
antigen presentation and inhibition of inﬂammation is induced by
immunosuppresive cytokines IL-10 and TGF-β and also by glucocor-
ticoids. In addition, macrophages involved in the clearance of
apoptotic cells present an immunosuppressive phenotype due to
their active production of IL-10 and TGF-β and other anti-inﬂamma-
tory mediators [102,103].
7. LXRs and other nuclear receptors in inﬂammation pathways
Several NRs, in addition to their roles in development and
metabolism, can function as modulators of the innate and adaptive
immune responses. Due to their clinical implications and their potent
anti-inﬂammatory properties, the steroid glucocorticoid responses
mediated by GR have been extensively investigated [10,104].
Numerous studies have also implicated PPARs and more recently
LXRs in the modulation of macrophage inﬂammatory gene expres-
sion. Although the GR and PPARmediated actions inmacrophages will
not be revised here (readers should visit recent reports by Glass and
Saijo [10] and Chawla [105] for more details), some important
concepts were identiﬁed by studying these receptors and will be
brieﬂy mentioned here.
As outlined above, some NRs, in addition to the positive regulation
of transcription that is generally achieved by binding to their speciﬁc
HREs, can also inhibit the transcriptional activity of other transcrip-
tion factors which usually requires protein–protein interactions
without direct DNA binding [10]. Interestingly, several repression
mechanisms mediated by NRs can inﬂuence the activity of other
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and STAT.Many differentmechanisms have been described in order to
explain the NR-dependent repression of inﬂammatory gene expres-
sion and are usually referred as “transrepression.” Since the early
studies by the Evans and Karin laboratories that reported a mutual
repression of GR and AP-1 activities [106,107], several different
mechanisms of transpression have been described for GR [10,108],
PPAR and LXR (see review by Glass and Saijo [10] and others in this
series of BBA reviews). A novel transrepression mechanism was
reported in 2005 by Pascual et al. [109] who demonstrated how
ligand-activated PPARγ inhibits the expression of inducible nitric
oxide synthase (iNOS) that was studied as a prototypic inﬂammatory
gene that is sensitive to NR-dependent transrepression. This mech-
anism includes a ligand-dependent SUMOylation (through the SUMO
E2 ligase, Ubc9 and the SUMO E3 ligase protein inhibitor of activated
STAT1, PIAS1) of the PPARγ LBD that targets the receptor to
correpresor complexes present in inﬂammatory promoters, thereby
preventing the recruitment of the ubiquitin-conjugating enzyme
(Ubch5) and the subsequent degradation machinery necessary for
correpresor removal in response to pro-inﬂammatory challenges
[109]. Under these circumstances, the NCoR complex remains bound
to the promoter region and the expression of inﬂammatory genes is
preserved as a repressed state [109].
Prior to these mechanistic studies, work by the Tontonoz
laboratory in 2003 described an LXR-dependent repression of
inﬂammatory gene expression in activated macrophages [110].
These studies indicated that, in addition to inducing genes involved
in reverse cholesterol transport, LXRs inhibit a set of inﬂammatory
genes after, LPS, TNF-α, or IL-1β stimulation [48,110,111]. Examples
of such genes include those involved in generation of bioactive
molecules such as iNOS and COX-2, cytokines IL-6 and IL-1β, the
chemokines monocyte chemoattractant protein-1 (MCP-1) and MCP-
3, and MMP-9. LXR ligands are able to repress the expression of those
genes in macrophages derived from WT, LXRα−/−, and LXRβ−/−
mice but are unable to do so in macrophages from LXRαβ−/− mice,
indicating that both LXR isoforms can mediate the anti-inﬂammatory
activity of the speciﬁc agonists [110]. Experiments in vivo conﬁrmed
the antiinﬂammatory effects of LXRs; for example LXRαβ−/− mice
exhibit an exacerbated systemic inﬂammatory response when
challenged intraperitoneally with bacterial LPS. Also, structurally
unrelated LXR agonists reduce skin inﬂammation in amodel of irritant
contact dermatitis [110,112]. Around that time, the Feingold labora-
tory reported a similar result using the allergic dermatitis model in
mice and also found that LXR ligands presented similar anti-
inﬂammatory actions to those observed with a steroid-based drug
[112]. More recent studies by Ghisletti et al. [113] described a parallel
mechanism comparable to the one described for PPARγ-dependent
transrepression by which LXRs inhibit the expression of inﬂammatory
genes. In this case, ligand-activated LXRs preserve the integrity of the
corepressor complexes at the inﬂammatory promoters by interacting
with HDAC4 E3 ligase and SUMO2/3 to prevent inﬂammatory signal-
dependent activation [113]. This NCoR-dependent transrepression
mechanism has also been shown to be involved in the inhibition of C-
reactive protein expression in hepatocytes [114]. Other studies
demonstrated that SUMOylation of LXRs is required for the suppres-
sion of STAT1-dependent inﬂammatory responses induced by in IFNγ
[115]. Moreover, a recent report demonstrated that the ability of LXRs
to prevent NCoR turnover and suppress the acute phase response in
the liver requires the G protein pathway suppressor 2 (GPs2) for the
docking of SUMOylated LXR within the target promoters [116]. Thus,
ligand-dependent SUMOylation of PPARs and LXRs plays a relevant
role antagonizing several inﬂammatory situations. However, an
integrative mechanism that explains how the cellular pool of liganded
receptor/s can promote transactivation (through NCoR/SMRT clear-
ance) and transrepression (through SUMO-NCoR retention) in the
same cell at the same time remains to be elucidated.Transcriptional proﬁling studies by Ogawa et al. demonstrated
that GR, PPAR and LXR ligands are able to inhibit the expression of a
signiﬁcant proportion of genes induced by LPS/TLR4 signaling in
macrophages [117]. Interestingly, some groups of genes were
transcriptionally repressed by all three receptors, although the
complete list of transrepression signature of each individual
receptor is only partially overlapping suggesting that GR, PPAR
and LXR are likely using distinct coregulators for their repressive
functions. Moreover, detailed analysis of the promoter regions of
the repressed genes demonstrated that many of them present
regulatory regions containing NFκB, AP-1 and ISRE consensus
binding sites but not HREs, indicating that the anti-inﬂammatory
properties of these receptors are, to a large extent, mediated
through transrepression mechanisms [117]. However, the potential
for these nuclear receptors to directly upregulate the expression of
anti-inﬂammatory molecules through transactivation mechanisms
under physiological or pathological circumstances has only been
partially explored. For example, studies by the Karin and Baldwin
laboratories reported that glucocorticoids induce the expression of
IκBα, thereby preventing the binding of NFκB to its target
promoters as a plausible mechanism for the anti-inﬂammatory
action of glucocorticoids in certain cells [118,119]. Other studies
have proposed a role for PPARγ as a regulator of macrophage M1/
M2 transition. First, Glass and colleagues described the induction of
PPARγ expression by the Th2 cytokine IL-4, which also stimulates
cellular generation of natural PPARγ ligands through the 12/15-
lipoxygenase pathway [120]. More recently, contributions from
several laboratories showed that PPARγ and PPARδ are important
players in the polarization of macrophages with anti-inﬂammatory
properties by inducing alternative M2-dependent genes (such as
arginase I and others) and through collaboration with other
transcription factors (such as STAT6) important for M2 polarization
[121–128].
Despite their important role in the reverse cholesterol pathway
and their inhibitory effects on inﬂammatory gene expression, the
contribution of LXRs in macrophage polarization in the context of
obesity and insulin resistance appear to be less prevalent [129].
However, LXRs also participate in the regulation of glucose metabo-
lism in the liver and adipose tissue and LXR agonists showed a
signiﬁcant effect as insulin-sensitizing factors in murine models of
diet-induced obesity [130,131].
LXRs have also been shown to positively regulate the expression of
the anti-inﬂammatory enzyme arginase II in macrophages [132]. Both
arginase I and arginase II enzymes participate in the ﬁnal steps of the
urea cycle and catalyze the conversion of L-arginine to L-ornithine.
Arginase activity in macrophages contributes to the metabolization of
nitrogen into polyamines, a process that is important for cellular
proliferation and wound healing. In addition, arginase expression
contributes to substrate competition with other arginine-dependent
enzymes, such as iNOS, and has thus the potential to exert anti-
inﬂammatory effects by the inhibition of nitric oxide production.
Interestingly, stable expression of arginase II in macrophages leads to
decreased nitric oxide (NO) production but not iNOS expression after
engagement of TLR signaling [132]. Even though arginase activity may
function to prevent excessive NO production and promote wound
healing, iNOS activity is a crucial cytotoxic mechanism to control
pathogen growth and deﬁcient NO production could in turn
compromise anti-microbial responses. Consistent with this idea,
inhibition of arginase activity in macrophages (either pharmacolog-
ically or genetically) favors host immune responses against infections
with Leishmania major, Mycobacterium tuberculosis or Toxoplasma
gondii [133,134]. Conversely, induction of arginase I expression by
PPARγ/δ agonists (as well as other markers of M2 polarization)
promotes the growth of L. major in macrophages [127], whereas
macrophage-speciﬁc PPARγ−/−mice are less susceptible to infection
by L. major in vivo [122].
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As summarized above, LXRs inhibit the LPS or cytokine-induced
expression of inﬂammatory genes in macrophages [110,111,113,117,
135], suggesting that pharmacological strategies that promote LXR
activity may be useful to reduce the deleterious effects of inﬂamma-
tory diseases. In the last several years, many research groups have
studied the role of LXRs in different mouse models of inﬂammatory
disease. In models of diet-induced atherogenic inﬂammation, such as
ApoE−/− and LDLR−/−mice, administration of LXR ligands reduced
the aortic expression of inﬂammatory genes, such as of MMP-9 and
tissue factor while inducing expression of the cholesterol transporters
ABCA1 and ABCG1 [110,136].
The biological functions of LXRs are important to maintain
homeostasis in the CNS by controlling lipid metabolism and many
of these aspects have been extensively investigated by the Gustafsson
group [137–139]. Recent studies have also explored a potential impact
of LXRs in the brain with special focus on some inﬂammatory
conditions in models of Alzheimer's disease [140,141], experimental
autoimmune encephalitis (EAE)[142] or ischemic stroke [141,143–
146]. Interestingly, these studies demonstrated, by either synthetic
LXR ligand administration or receptor deletion, that LXRs play an
important role in controlling inﬂammatory signaling in vivo in the
brain.
LXRs also present some therapeutic value in the context of skin
inﬂammation. As mentioned before, LXR ligands effectively limit the
inﬂammatory response in models of allergic dermatitis [110,112]. In
addition, modulation of LXR activity alleviates the damage in the skin
caused by photoaging and also modulates inﬂammatory gene
expression in keratinocytes derived from skin biopsies of human
psoriatic lesions [147,148]. Other recent reports demonstrated the
potential for LXRs to reduce inﬂammation and tissue damage in the
lung [149,150].
The connection between inﬂammatory pathways and LXR signal-
ing may have an impact in anti-microbial responses in normal
physiology, because as mentioned above, profound reduction of
inﬂammatory gene expression in macrophages may compromise host
defense against pathogens. Surprisingly, as ﬁrst reported by Joseph et
al. in 2004 [39], loss of LXR function leads to ineffective innate
immune responses. Mice lacking LXRs are more susceptible to
infection with the Gram-positive intracellular pathogen Listeria
monocytogenes (LM). Susceptibility to infection was recapitulated by
transplantation of bone marrow from LXR-deﬁcient mice into WT
mice, suggesting that LXR function in hematopoietic cells is required
for a correct immune response against LM [39]. The celerity of the
disease observed in LXR-deﬁcient mice is consistent with a defect in
innate immunity and correlated with accelerated rates of macrophage
apoptosis, indicating that altered macrophage function in response to
infection was a major contributor to the observed susceptibility.
Interestingly, macrophage survival has been also suggested as an
important mechanism that contributes to mount an appropriate
response to LM infection [151,152]. Surprisingly, LXRα−/− were
found to be particularly sensitive to LM infection and macrophage
apoptosis. The survival of macrophages in response to infection is
sustained, at least in part, by LXRα-dependent expression of the anti-
apoptotic gene AIM/Spα [153]. Moreover, stable expression of either
AIM or LXRα inmacrophages promotes bothmacrophage survival and
anti-microbial mechanisms during LM infection [39]. At the same
time, Valledor et al. [154] independently found that LXR signaling also
inhibits macrophage apoptosis in response to cytokine withdrawal,
toxic drugs or infectionwith the bacteria Bacillus anthracis, Escherichia
coli or Salmonella typhimurium. They found that LXR activity was
important for the induction of anti-apoptotic genes, including AIM,
Bcl-xL and Birc1a and the inhibition of a other pro-apoptotic genes in
response to inﬂammatory stimuli [154]. In addition to being induced
in the setting of bacterial infection, AIM expression was also found tobe upregulated during macrophage cholesterol loading in an LXR-
dependent manner [155]. The ability of the LXR pathway to enhance
macrophage survival in the context of infection and lipid overload (in
part through the induction of AIM and other anti-apoptotic genes)
also highlights that common pathways are utilized for both metabolic
and immune control. Recently, Korf et al. demonstrated that mice
lacking LXRα were also more susceptible to infection with Mycobac-
terium tuberculosis, likely through dysregulation of Th1/Th17 function
in the lungs upon bacterial infection [156].
An additional connection between lipid metabolism and immunity
in macrophages via the LXR pathway was demonstrated in other
studies by the Tontonoz laboratory [157], where they demonstrated
that infections with bacterial pathogens, such as E. coli or the RNA
virus inﬂuenza A inhibit the function of LXRs in cholesterol
homeostasis. Expression of ABCA1, ABCG1, apoE and the efﬂux of
cholesterol to extracellular acceptors was signiﬁcantly inhibited in
bacterial or viral infectedmacrophages. These effects can bemimicked
by activation of members of the Toll-like receptor (TLR) family,
speciﬁcally TLR3, which recognizes double-stranded RNA generated
during viral infections or TLR4, the LPS receptor. In addition, the use of
macrophages deﬁcient in various components of the TLR signaling
pathway demonstrated that TLR3/4-dependent inhibition of choles-
terol efﬂux was mediated by the transcription factor IRF3 and is
independent of MyD88 and NFκB [157]. Interference with LXR-
dependent cholesterol metabolism by infections might aggravate the
process of foam cell accumulation during atherogenesis and exacer-
bate atherosclerotic lesions formation. This idea has been investigated
in recent studies demonstrating that LXRs can also modulate the TLR-
dependent foam cell formation in Chlamydia pneumoniae infected
macrophages [158–160]. Moreover, Chlamydia pneumoniae-induced
atherosclerosis in the ApoE−/− model was signiﬁcantly accelerated
in the absence of LXRα that presented increased serum inﬂammation
and accumulation of lipids and myeloid cells in the aortas of these
animals [159].
In addition to the importance of LXRs in macrophages, recent
studies have focused their research in the biology of LXRs in other
cells of the immune system, such as dendritic cells and lymphocytes
[20,161–165]. One of the key recent ﬁndings was reported by
Bensinger et al. [164], who demonstrated an unexpected link between
sterol metabolism, LXR, and adaptive immune responses. They
showed that T cell activation by mitogens correlates with the
downregulation of LXR cholesterol efﬂux target genes and the
simultaneous induction of the SREBP-2 pathway for cholesterol
synthesis. In addition, signals that promote lymphocyte expansion
also induce the expression of oxysterol sulfotransferase (SULT2B1), an
enzyme that catalyzes the transfer of sulfate groups to oxysterols,
inactivating them as LXR ligands. These important characteristics
found in lymphocytes improve the uptake and de novo synthesis of
cholesterol for membrane formation and allow lymphocytes to
undergo rapid proliferation in response to antigens. Activation of
LXRs with synthetic agonists inhibits T cell proliferation by promoting
cholesterol efﬂux and thus limiting cellular sterol content. Conversely,
increased proliferation was observed in LXR-deﬁcient lymphocytes,
resulting in enhanced homeostatic and antigen-driven responses.
Interestingly, LXR agonists did not inhibit lymphocyte expansion in
cells obtained from LXRβ-deﬁcient mice (which is the main LXR
isoform expressed in lymphocytes). The authors also found that the
effects of LXR activation in T cell proliferation were signiﬁcantly
reduced in cells lacking ABCG1 [164]. These results indicate that
during the T cell activation process the LXR-dependent cholesterol
transport must be downregulated by limiting the cellular content of
active oxysterols (through SULT2B1), and through the inhibition of
ABCG1 expression. The ability of LXR cholesterol metabolic pathways
to modulate lymphocyte expansion reported by Bensinger et al. [164]
indicate that cellular sterol metabolism is a novel signaling pathway
regulating T cell function and acquired immune responses.
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As outlined above, tissue macrophages also play a key role in the
clearance of apoptotic cells. In multicellular organisms billions of
apoptotic cells are generated every day that culminate in recognition
and ingestion by phagocytes [166]. The uptake/engulfment of
apoptotic cells (also known as “efferocytosis” taken from the Latin
“effero,” meaning to take the corpse to the grave [167]) is a complex
process that occurs through a series of controlled events. Apoptotic
cells generate “ﬁnd me” signals, such as lipids or recently identiﬁed
nucleotides ATP/UTP, to recruit macrophages and other phagocytes at
sites of cell death [168–170].Whenmacrophages reach the dying cells,
they recognize “eatme” signals exposed on the surface of the apoptotic
cells. These elements displayed on the outside of the dying cell are
usually lipid or carbohydrate changes, such as phosphatidylserine
(PtdSer), a membrane lipid normally restricted to the inner leaﬂet of
the plasma membrane [166]. Recognition of PtdSer is mediated either
directly throughPtdSer receptors, includingBai1 andTim-4, or through
bridging molecules including MFGE8, GAS6, ProS or C1q that bind
PtdSer on the outside of the dying cell and phagocyte receptors such as
TAM family (Tyro3, Axl, and Mer) and αvβ3-integrin (see recent
review and references by Ravichandran [171]). Efﬁcient disposal of
apoptotic cells prevents the loss of cellular integrity, uncontrolled
release of intracellular contents and secondary necrosis. In addition,
macrophages ingesting apoptotic cells activate tolerogenic pathways
in an effort to prevent immune responses against intracellular
antigens. Immunosuppression is mediated through the inhibition of
M1 classic activation and the release of anti-inﬂammatory molecules
such as IL-10 and TGFβ [102,103]. If the engulfment process or
tolerogenic pathways are impaired, chronic accumulation of immu-
nogenic targets can have pathological consequences, including several
autoimmune disorders, such as systemic lupus erythematosus (SLE)
(see recent review [172]). Given the important role of several NRs in
lipid metabolism and inﬂammatory pathways and that engulfment of
dying cells signiﬁcantly increases the amount of intracellular lipids, we
and others have recently studied the role of LXRs and PPARs during the
clearance of apoptotic cells by macrophages.
Gonzalez et al. [173] demonstrated that engulfment of apoptotic
thymocytes (ATs) in vitro, but not bacteria or inert beads, is severely
compromised in LXR-deﬁcient macrophages. Phagocytosis of apopto-
tic cells by macrophages is signiﬁcantly enhanced by the treatment
with an LXR agonist. These LXR-dependent pathways are also active in
vivo, as demonstrated by three complementary approaches. First,
LXR-null resident macrophages presented less engulfment capacity
than WT controls upon an intraperitoneal challenge of ATs. Second,
forced apoptosis of cortical thymocytes of mice injected with
dexamethasone (WT and LXR-deﬁcient thymocytes present compa-
rable sensitivity to apoptosis) resulted in accumulation of large
amounts of unengulfed ATs in LXR-deﬁcient thymi, indicating that
loss of LXR function results in defective clearance of an acute burden
of apoptotic cells. Third, loss of LXR function for apoptotic cell
clearance leads to defective disposal of unwanted cells in vivo and
impaired tissue homeostasis as many free apoptotic cells are
visualized in LXR-deﬁcient mice, including spleen, thymus, lung and
testis [173]. Transcriptional proﬁling and in vitro expression assays
identiﬁed the apoptotic cell receptor Mer (that belongs to the Tyro3,
Axl, andMer (TAM) receptor tyrosine kinase family; see recent review
by Lemke [174]) as a novel LXR target gene. These TAM receptors and
their ligands Gas6 and Protein S are required for the optimal
phagocytosis of apoptotic cells in the mature immune, nervous, and
reproductive systems [174]. In our studies in mousemacrophages, the
expression of Axl, Tyro3, their ligands GAS6/ProS, and other bridging
molecules such as MFGE8 was not altered by LXR ligands. In contrast,
expression of Mer was induced in macrophages and in vivo in several
tissues in response to LXR agonists, and reduction of Mer expression
resulted in reduced phagocytosis induced by LXR ligand, indicatingthat LXR signaling promotes the clearance of apoptotic cells, at least in
part, through induction of Mer expression. A recent report has also
investigated the role of LXRs in the context of apoptotic cell clearance
by human peripheral blood monocyte derived macrophages in vitro.
In this study, Rébé et al. [175] found that LXR activation induces the
expression of retinoid acid receptor α (RARα) by direct binding and
transactivation of the RARα promoter in human macrophages.
Combination of speciﬁc ligands for LXR and RAR synergistically
induces the expression of tissue transglutaminase (TGM2), a known
retinoid-regulated gene [176,177] and an important factor involved in
phagocytosis [178]. Consistent with these changes in gene expression,
human macrophages cultured with LXR ligand, RAR ligand, or
combination of both stimulated the ability of these macrophages to
engulf apoptotic cells. This study suggests that activation of LXRs in
human macrophages can further promote RARα-dependent gene
expression (including TGM2) that can additionally contribute to the
clearance of apoptotic cells [175].
Ingestion of apoptotic cells is coupled to the suppression of
inﬂammation and leads to increased cholesterol content inside the
macrophages. Previous work demonstrated that ABCA1 is important
for efﬁcient phagocytosis of apoptotic cells [179]. Also, macrophages
engulﬁng apoptotic cells promote the expression of ABCA1 [180–182],
thereby promoting cholesterol efﬂux and compensating the levels of
intracellular lipids. We found that the expression of Mer and many
other known LXR targets involved in lipid metabolism were
upregulated by apoptotic cells in WT, but not in LXR-deﬁcient
macrophages, suggesting that LXR regulates the expression of a
speciﬁc subset of genes that accelerate corpse removal and maintain
lipid metabolism in response to apoptotic cell uptake [173]. We also
found that LXR is involved in the macrophage deactivation process
induced by apoptotic cells, as inhibition of inﬂammatory cytokine
production by macrophages engulﬁng apoptotic cells is severely
impaired in LXR-null cells. Moreover, we observed that intact LXR
function is required for correct transactivation of anti-inﬂammatory
cytokines such as TGF-β and IL-10 in response to apoptotic cells. These
clearance and immunosuppressive defects might cause the initiation
and maintenance of systemic autoimmune reactions and chronic
inﬂammation in LXR-deﬁcient mice. This idea is also supported by
several mouse models in which defective apoptotic cell clearance
leads to an autoimmune phenotype, including mice lacking Mer,
MFGE8, C1q, Tim-4 orαvβ3/5 [183–187]. Also, some groups of patients
with systemic lupus erythematosus (SLE) present both in vitro and in
vivo deﬁciencies in their ability to clear apoptotic cells [172]. We
observed that LXR-null mice show age-dependent splenomegaly,
lymphadenopathy and elevated levels of antibodies to nuclear
proteins (ANA antinuclear antibodies), double-stranded DNA
(dsDNA), and histones were detected in their serum. Moreover,
LXRαβ−/− mice presented inﬁltration of immune cells and deposi-
tion of IgG-containing immune complexes in several tissues including
skin, lung and kidney that contribute to compromised renal functions
[173]. These results are consistent with the development of age-
dependent, systemic autoimmune disease due to autoantibody
production and chronic inﬂammation. We have also shown that
pharmacological activation of LXR might have therapeutical effects
against autoimmunity. Chronic administration of the synthetic LXR
agonist GW3965 to B6lpr/lpr (a mild model of lupus-like disease)
ameliorated the progression of autoimmune disease in these mice
[173]. Together, our contributions demonstrate that LXRs participate
in transcriptional responses crucial to maintain tissue homeostasis in
response to apoptotic cells. Engulfment of apoptotic cells activates
LXRs, likely through the accumulation of sterol-derived ligands for
LXRs, and facilitates effective clearance by a feed-forward mechanism
through the induction of Mer. Also, LXRs participate in the
immunosuppression actions of apoptotic cells by inhibiting the
production of pro-inﬂammatory mediators and are crucial for the
maintenance of immune tolerance.
989N. A-González, A. Castrillo / Biochimica et Biophysica Acta 1812 (2011) 982–994In addition to these investigations with LXRs, recent studies have
also implicated other NRs in the phagocytosis of apoptotic cells. An
interesting study was recently reported by Chawla and colleagues
[188] that found a parallel pathway triggered by apoptotic cells
through the activation of PPARδ signaling in macrophages that is
important for apoptotic cell clearance and immune tolerance.
Remarkably, global or macrophage-speciﬁc PPARδ-null mice devel-
oped spontaneous autoimmunity. They showed that PPARδ regulates
expression of various bridging molecules, such as complement 1qb
(C1qb) and MFGE8 [188]. Defective expression of these opsonins in
other mouse models contribute to systemic autoimmune disease and
some aberrant forms of these proteins in humans are found in patients
with SLE [185,189].
Using pharmacological tools and in vitro assays, several reports
have previously suggested a possible involvement of PPARγ during
the clearance of apoptotic cells in macrophages and dendritic cells
[190–193], although the in vivo relevance of these observations
remains to be established. Other studies have also demonstrated that
glucocorticoid-treatedmacrophages have increased capacity to engulf
apoptotic cells [194,195]. Recent work has additionally demonstrated
that these effects are likely due to GR-dependent transactivation of
MFGE8, C1qa, ProS and Mer [196,197].
10. Conclusions
Over the past several years, signiﬁcant progress has been made to
increase our understanding of LXR functions in physiology and
disease. It is clear that regulation of cellular and systemic cholesterolFig. 1. Nuclear receptors LXRs and PPARδ contribute to efﬁcient engulfment of apoptotic ce
signals displayed on the surface of apoptotic cells. Bridging molecules also contribute to th
releases native or oxidized sterols and fatty acids derivatives that are capable of transactiv
tyrosine kinase receptor, Mer, thereby promoting further clearance of apoptotic cells. Ingesti
in an LXR-dependent manner. Activation of PPAR-δ, on the other hand, induces the produ
recognition by surface receptors. Both nuclear receptor signaling cascades also lead to a po
response to self-antigens and inﬂammation.levels, with special relevance in the reverse cholesterol transport
pathway, is the prominent function of LXRs. The recently identiﬁed
LXR–Idol pathway that can modulate circulating LDL cholesterol
levels reinforces the idea of LXRs as whole body cholesterol sensors.
In macrophages, LXRs not only play a crucial role in the
modulation of lipid metabolism but also display important functions
in inﬂammation and host defense. A signiﬁcant portion of the anti-
inﬂammatory effects of LXRs are likely accomplished through
transrepression mechanisms and a similar scenario may also be
applied for PPARs and GR speciﬁc functions during inﬂammation.
Some aspects of this dual role of LXRs and other NRs as regulators of
both activation and repression raise new questions and deserve
further investigation. Given that correpresor clearance or retention is
crucial for ligand-dependent transactivation or transrepression,
respectively, what are the speciﬁc signals that coexist in the same
cell and guide a liganded nuclear receptor to a positively or a
negatively regulated gene? Are there other post-translational mod-
iﬁcations (in addition to SUMOylation) important to discriminate
between transactivation or transrepression? Are there other coregu-
lator partners being recruited to the transrepressive or transactivating
promoters in response to speciﬁc challenges in vivo? Are these
molecular mechanisms fully operative in human monocytes, macro-
phages or dendritic cells? These and other questions may be relevant
to design new ligands that could dissociate between transactivation of
lipid metabolic genes and transrepression of inﬂammatory genes.
New developments related to PPARγ changes in speciﬁc phosphor-
ylation sites in response to ligand that can dissociate between its
adipogenic and antidiabetic capacities [198] indicate that additionallls by macrophages. Phagocytes express membrane receptors that recognize “eat me”
e binding and engulfment of the dying cell. Intracellular processing of apoptotic cells
ating LXRs and PPARδ, respectively. Activation of LXRs promotes the expression of the
on of apoptotic cells also enhance the expression of genes involved in cholesterol efﬂux
ction of opsonins C1q and MFGE-8 that help the coating of apoptotic cells and their
tent immunosuppressive action on the macrophage, contributing to avoid an immune
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shown by Medzhitov and colleagues [199] that GR activation inhibits
the expression of many pro-inﬂammatory genes in recurrent LPS
challenges (amodel of endotoxin tolerance) inmacrophages, whereas
numerous anti-microbial genes important to clear infections remain
unchanged or even exhibit upregulated expression in dexamethasone
treated macrophages. Since many anti-microbial and anti-inﬂamma-
tory genes are regulated by common transcription factors, their
results suggest that additional co-factors/modiﬁcations are responsi-
ble for this selective repression [199].
We propose an additional point of view to integrate some of our
recent advances. As outlined above, both LXRs and PPARs induce the
expression of speciﬁc targets in macrophages that may predispose
these cells to exhibit a more anti-inﬂammatory, tissue repair
phenotype. For example, regulation of the arginase family of enzymes
by PPARγ/δ and LXRs may have implications in macrophage
transcriptional programs by reducing their inﬂammatory status. In
addition, efﬁcient disposal of dying cells triggers potent immunosup-
pressive signals such as IL-10 and TGF-β cytokines, and both LXRs and
PPARδ regulate this apoptotic clearance process in vivo by inducing
the expression of phagocytic receptor Mer and bridging molecules
C1qb and MFGE8 (see Fig. 1). It is likely that GR (through the
induction of ProS) and perhaps other NRs such as RARα or PPARγmay
also be involved in these responses in vivo as well. Defects in
apoptotic cell clearance observed in LXR and PPARδ null mice lead to
age-dependent systemic autoimmune disease, a phenotype also
observed in Mer, MFGE8 and C1q-deﬁcient mice. In addition, Mer
signaling is directly linked to pleiotropic anti-inﬂammatory properties
by antagonizing TLR signaling in macrophages and dendritic cells
[174]. Therefore, activation of LXRs during the normal disposal of
apoptotic cells in vivo by tissue resident macrophages promotes
further clearance and anti-inﬂammatory gene expression. Together,
some of our recent results indicate that LXR signaling couples the
engulfment of apoptotic cells to the suppression of inﬂammatory
pathways and further illustrate that the activation and transrepres-
sion functions of LXRs are both important for normal immune
homeostasis. Future work along these lines will continue to deﬁne
the roles of LXRs in immunity and metabolism.
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